GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
March 21, 2024 at 03:25 AM EDT
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
